Sfoglia per Autore
Does P-glycoprotein-170 expression predict for chemoresistance in transitional cell carcinoma of the bladder?
2002-01-01 Sanguedolce, R.; Calascibetta, A.; Porcasi, R.; Melloni, D.; Pavone, C.; Maria Tomasino, R.; Pavone-Macaluso, M.
The significance of the Thymidylate Synthase expression in the Signet Ring Cell component of colorectal carcinoma
2004-01-01 CALASCIBETTA A; CAMPIONE M; BARRESI E; RAUSA L; DARDANONI G; ARAGONA F; SANGUEDOLCE R
Thymidylate synthase gene promoter polymorphisms are associated with TSmRNA expressions but not with microsatellite instability in colorectal cancer
2004-01-01 CALASCIBETTA A; CABIBI D; MARTORANA A; SANGUEDOLCE G; RAUSA L; FEO S; DARDANONI G; SANGUEDOLCE R
LOW CELL PROLIFERATION AND LOW THYMIDYLATE SYNTHASE LEVELS IN THE HIGHLY AGGRESSIVE SIGNET RING CELL VARIANT HISTOTYPE OF COLORECTAL CARCINOMA
2004-01-01 SANGUEDOLCE R; M CAJOZZO; L RAUSA; F ARAGONA; G SANGUEDOLCE; G DI FEDE; A CALASCIBETTA
Clinical relevance of thymidylate syntetase expression in the signet ring cell histotype component of colorectal carcinoma
2004-01-01 CABIBI, D; CALASCIBETTA, A; CAMPIONE, M; BARRESI, E; RAUSA, L; DARDANONI, G; ARAGONA, F; SANGUEDOLCE, R
Thymidylate Synthase polymorphism and microsatellite instability: association in colorectal cancer
2004-01-01 CALASCIBETTA A; RAUSA L; GULLOTI L; BUETTNER R; SANGUEDOLCE R
Low cell proliferation marker and low thymidylate synthase levels in the highly aggressive signet ring cell variant histotype of colorectal carcinoma
2004-01-01 SANGUEDOLCE R; CABIBI D; CAJOZZO M; RAUSA L; ARAGONA F; SANGUEDOLCE G; DI FEDE G; CALASCIBETTA A
Low cell proliferation marker and low thymidylate synthase levels in the highly aggressive signet ring cell variant histotype of colorectal carcinoma
2004-01-01 SANGUEDOLCE R; CABIBI D; CAJOZZO M; RAUSA L; ARAGONA F; SANGUEDOLCE G; DI FEDE G; CALASCIBETTA A
Relationship between the thymidylate synthase, p53 levels and the treatment by CMF drug combination versus taxanes in the locally advanced carcinoma of breast.
2005-01-01 SANGUEDOLCE R; RAUSA L; CABIBI D; ARAGONA F; BARRESI E; MARTORANA A; CALASCIBETTA A
Difference in Ki67 and Thymidylate synthase expression in primary tumour compared with metastatic nodes in breast cancer patients
2005-01-01 RAUSA L; CALASCIBETTA A; CABIBI D; ARAGONA F; BARRESI E; MARTORANA A; SANGUEDOLCE R
Relationdhip between the thymidylate synthase, P53 levels and the treatment by CMF drug combination versus taxanes in the locally advanced carcinoma of breast
2005-01-01 SANGUEDOLCE R; RAUSA L; CABIBI D; ARAGONA F; BARRESI E; MARTORANA A; CALASCIBETTA A
Difference in ki67 and thymidylate synthase expression in primary tumour compared with metastastic nodes in breast cancer patients
2005-01-01 CALASCIBETTA A; CABIBI D; RAUSA L; ARAGONA F; BARRESE E; MARTORANA A; SANGUEDOLCE R
RELATIONSHIP BETWEEN THE THYMIDYLATE SYNTHASE, p53 LEVELS AND THE TREATMENT BY CMF DRUG COMBINATION VERSUS TAXANES IN THE LOCALLY ADVANCED CARCINAMO OF THE BREAST
2005-01-01 SANGUEDOLCE R; RAUSA L; CABIBI D BARRESI E; MARTORANA A; CALASCIBETTA A
Relationship between the thymidiylate synthase, P53 levels and the treatment by CMF drug combination versus taxanes in the locally advanced carcinoma of the breast
2005-01-01 SANGUEDOLCE R; RAUSA L; CABIBI D; ARAGONA F; BARRESI E; MARTORANA A; CALASCIBETTA A
Difference in ki67 and thymidylate synthase expression in primary tumour compared with metastastic nodes in breast cancer patients. european society for the study of purine and pyrimidine metabolism in man
2005-01-01 CALASCIBETTA A; RAUSA L; CABIBI D; ARAGONA F; BARRESI E; MARTORANA A; SANGUEDOLCE R
Lymph node metastases displaying lower Ki-67 immunostaining activity than the primary breast cancer
2006-01-01 CABIBI D; MUSTACCHIO V; MARTORANA A; TRIPODO C; CAMPIONE M; CALASCIBETTA A; SANGUEDOLCE R; ARAGONA F
Difference in Ki67 and thymidylate synthase expression in primary tumour compared with metastatic nodes in breast cancer patients.
2006-01-01 CALASCIBETTA A; CABIBI D; RAUSA L; ARAGONA F; BARRESI E; MARTORANA A; SANGUEDOLCE R
Relationship between thymidylate synthase expression and p53 levels with the treatment of cyclophosphamide, methotrexate, 5-fluorouracil chemotherapy(CMF) versus docetaxel (TXT) in locally advanced carcinoma of the breast.
2006-01-01 M BRANDI; A CALASCIBETTA; D CABIBI; A MARTORANA; F ARAGONA; FULFARO F; M VALERIO; J DISPENZA; R SANGUEDOLCE
Relationship between the thymidylate synthase, p53 levels with the treatment by Cyclophosphamide, Metotrexate, 5-Fluorouracil chemotherapy (CMF) versus Docetaxel (TXT) in the locally advanced carcinoma of breast.
2006-01-01 BRANDI M; CALASCIBETTA A; CABIBI D; MARTORANA A; ARAGONA F; FULFARO F; VALERIO M; DISPENSA J; SANGUEDOLCE R
Relationship between thymidylate synthase expression and p53 levels with the treatment of cyclophsphamide, methotrexate, 5-fluorouracil chemotherapy ( CMF)versus docetaxel ( TXT) in locally advanced carcinoma of the breast
2006-01-01 BRANDI M; CALASCIBETTA A; CABIBI D; MARTORANA A; ARAGONA F; FULFARO M; VALERIO M; DISPENZA J; SANGUEDOLCE R
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile